Summary:
The reduced tumor suppression activity of hypomorphic variants of the TP53 gene was used by Indeglia and colleagues to corroborate PADI4 as a p53 target. The study makes a noteworthy advancement in comprehending the downstream implications of TP53–PDI4, including potential predictions of survival and the efficacy of immunotherapy.
©2023 American Association for Cancer Research
2023
American Association for Cancer Research
You do not currently have access to this content.